Amgen Inc. (AMGN)
Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) James Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Olivia Brayer - Cantor Fitzgerald Michael Yee - Jefferies Courtney Breen - Bernstein Umer Raffat - Evercore ISI Terence Flynn - Morgan Stanley Jay Olson - Oppenheimer Carter Gould - Barclays Christopher Schott - JPMorgan Evan Seigerman - BMO Capital Markets Mohit Bansal - Wells Fargo Gregory Renza - RBC Capital Markets Matt Phipps - William Blair Christopher Raymond - Piper Sandler Operator My name is Julianne, and I will be your conference facilitator today for Amgen's Third Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amgen (AMGN) Beats Q3 Earnings Estimates
Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago.
Amgen posts higher 3rd-quarter profit, sales rise 24%
Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug Repatha and Prolia for osteoporosis, and said results of a mid-stage trial of a potentially lucrative obesity medicine will be unveiled late this year.
2 Reliable Dividend Stocks You Can Buy and Hold Forever
There are reasons beyond the dividends to invest in these stocks.
Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring on several blockbuster drugs will impact Amgen's revenue going forward, but new pipeline drugs hold significant potential for future growth. The weight-loss drug Mari-Tide could be a game-changer; positive Phase 2 data could significantly boost Amgen's market cap, and we might receive updates next week.
Ahead of Amgen (AMGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
Why Amgen (AMGN) Dipped More Than Broader Market Today
Amgen (AMGN) reachead $316.74 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
